Impact of host and virus genome variability on HCV replication and response to interferon

Current Opinion in Virology

Volumn 3, Issue 5, 2013, Pages 501-507

  Schweitzer, Cameron J ^a   Liang, T Jake ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BOCEPREVIR; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 9; INTERLEUKIN 28B; INTERLEUKIN 6; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON ALPHA; RIBAVIRIN; RNA BINDING PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; TELAPREVIR; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; DRUG TREATMENT FAILURE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOST; HUMAN; IN VITRO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRAL GENETICS; VIRUS CORE; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; GENETIC VARIATION; GENOME, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 84885952071     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2013.06.005     Document Type: Review

References (76)

1. C.W. Shepard, L. Finelli, and M.J. Alter Global epidemiology of hepatitis C virus infection Lancet Infect Dis 5 2005 558 567 (Pubitemid 41196755)
2. D. Lavanchy Evolving epidemiology of hepatitis C virus Clin Microbiol Infect: Off Publ Eur Soc Clin Microbiol Infect Dis 17 2011 107 115
3. H.B. El-Serag Epidemiology of viral hepatitis and hepatocellular carcinoma Gastroenterology 142 2012 1264 1273 e1261
4. T.J. Liang, and M.G. Ghany Current and future therapies for hepatitis C virus infection N Engl J Med 368 2013 1907 1917
5. D.L. Thomas, J. Astemborski, R.M. Rai, F.A. Anania, M. Schaeffer, N. Galai, K. Nolt, K.E. Nelson, S.A. Strathdee, and L. Johnson The natural history of hepatitis C virus infection: host, viral, and environmental factors JAMA: J Am Med Assoc 284 2000 450 456 (Pubitemid 30484478)
6. E. Kenny-Walsh Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group N Engl J Med 340 1999 1228 1233 (Pubitemid 29181642)
7. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, N.H. Bzowej, P. Marcellin, A.J. Muir, P. Ferenci, and R. Flisiak Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
8. P.Y. Kwo, E.J. Lawitz, J. McCone, E.R. Schiff, J.M. Vierling, D. Pound, M.N. Davis, J.S. Galati, S.C. Gordon, and N. Ravendhran Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 2010 705 716
9. A.U. Neumann, N.P. Lam, H. Dahari, D.R. Gretch, T.E. Wiley, T.J. Layden, and A.S. Perelson Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy Science 282 1998 103 107 (Pubitemid 28471138)
10. S. Duffy, L.A. Shackelton, and E.C. Holmes Rates of evolutionary change in viruses: patterns and determinants Nat Rev Genet 9 2008 267 276 (Pubitemid 351399833)
11. P. Farci New insights into the HCV quasispecies and compartmentalization Semin Liver Dis 31 2011 356 374
12. D.B. Smith, S. Pathirana, F. Davidson, E. Lawlor, J. Power, P.L. Yap, and P. Simmonds The origin of hepatitis C virus genotypes J Gen Virol 78 Pt 2 1997 321 328 (Pubitemid 27075628)
13. N.H. Afdhal, J.G. McHutchison, S. Zeuzem, A. Mangia, J.M. Pawlotsky, J.S. Murray, K.V. Shianna, Y. Tanaka, D.L. Thomas, and D.R. Booth Hepatitis C pharmacogenetics: state of the art in 2010 Hepatology 53 2011 336 345
14. G. Barba, F. Harper, T. Harada, M. Kohara, S. Goulinet, Y. Matsuura, G. Eder, Z. Schaff, M.J. Chapman, and T. Miyamura Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets Proc Natl Acad Sci U S A 94 1997 1200 1205 (Pubitemid 27087828)
15. R.G. Hope, and J. McLauchlan Sequence motifs required for lipid droplet association and protein stability are unique to the hepatitis C virus core protein J Gen Virol 81 2000 1913 1925 (Pubitemid 30599171)
16. C.N. Hayes, M. Kobayashi, N. Akuta, F. Suzuki, H. Kumada, H. Abe, D. Miki, M. Imamura, H. Ochi, and N. Kamatani HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy Gut 60 2011 261 267
17. N. Akuta, F. Suzuki, M. Hirakawa, Y. Kawamura, H. Yatsuji, H. Sezaki, Y. Suzuki, T. Hosaka, M. Kobayashi, and S. Saitoh Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin Hepatology 52 2010 421 429
18. K. Hayashi, Y. Katano, M. Ishigami, A. Itoh, Y. Hirooka, I. Nakano, F. Urano, K. Yoshioka, H. Toyoda, and T. Kumada Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy J Viral Hepat 18 2011 280 286
19. N. Akuta, F. Suzuki, H. Sezaki, Y. Suzuki, T. Hosaka, T. Someya, M. Kobayashi, S. Saitoh, S. Watahiki, and J. Sato Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy Intervirology 48 2005 372 380 (Pubitemid 41003622)
20. A. El-Shamy, I. Shoji, W. El-Akel, S.E. Bilasy, L. Deng, M. El-Raziky, D.P. Jiang, G. Esmat, and H. Hotta NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients J Clin Microbiol 50 2012 3886 3892
21. F. Ikeda, H. Dansako, G. Nishimura, K. Mori, Y. Kawai, Y. Ariumi, Y. Miyake, A. Takaki, K. Nouso, and Y. Iwasaki Amino acid substitutions of hepatitis C virus core protein are not associated with intracellular antiviral response to interferon-alpha in vitro Liver Int: Off J Int Assoc Study Liver 30 2010 1324 1331
22. Y. Funaoka, N. Sakamoto, G. Suda, Y. Itsui, M. Nakagawa, S. Kakinuma, T. Watanabe, K. Mishima, M. Ueyama, and I. Onozuka Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91 J Virol 85 2011 5986 5994
23. J.G. Bode, S. Ludwig, C. Ehrhardt, U. Albrecht, A. Erhardt, F. Schaper, P.C. Heinrich, and D. Haussinger IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3 FASEB J: Off Publ Fed Am Soc Exp Biol 17 2003 488 490
24. K. Melen, R. Fagerlund, M. Nyqvist, P. Keskinen, and I. Julkunen Expression of hepatitis C virus core protein inhibits interferon-induced nuclear import of STATs J Med Virol 73 2004 536 547 (Pubitemid 38857203)
25. A.R. Ciccaglione, E. Stellacci, C. Marcantonio, V. Muto, M. Equestre, G. Marsili, M. Rapicetta, and A. Battistini Repression of interferon regulatory factor 1 by hepatitis C virus core protein results in inhibition of antiviral and immunomodulatory genes J Virol 81 2007 202 214 (Pubitemid 44975161)
26. K. Inoue, K. Tsukiyama-Kohara, C. Matsuda, M. Yoneyama, T. Fujita, S. Kuge, M. Yoshiba, and M. Kohara Impairment of interferon regulatory factor-3 activation by hepatitis C virus core protein basic amino acid region 1 Biochem Biophys Res Commun 428 2012 494 499
27. A. Macdonald, and M. Harris Hepatitis C virus NS5A: tales of a promiscuous protein J Gen Virol 85 2004 2485 2502 (Pubitemid 39214345)
28. N. Enomoto, I. Sakuma, Y. Asahina, M. Kurosaki, T. Murakami, C. Yamamoto, N. Izumi, F. Marumo, and C. Sato Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region J Clin Investig 96 1995 224 230
29. N. Enomoto, I. Sakuma, Y. Asahina, M. Kurosaki, T. Murakami, C. Yamamoto, Y. Ogura, N. Izumi, F. Marumo, and C. Sato Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection N Engl J Med 334 1996 77 81 (Pubitemid 26017933)
30. K. Chayama, A. Tsubota, M. Kobayashi, K. Okamoto, M. Hashimoto, Y. Miyano, H. Koike, I. Koida, Y. Arase, and S. Saitoh Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection Hepatology 25 1997 745 749 (Pubitemid 27106464)
31. G.W. Witherell, and P. Beineke Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response J Med Virol 63 2001 8 16
32. C. Sarrazin, T. Berg, J.H. Lee, B. Ruster, B. Kronenberger, W.K. Roth, and S. Zeuzem Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response J Infect Dis 181 2000 432 441 (Pubitemid 30131807)
33. W.T. Hofgartner, S.J. Polyak, D.G. Sullivan, R.L. Carithers Jr., and D.R. Gretch Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b J Med Virol 53 1997 118 126 (Pubitemid 27445729)
34. A. El-Shamy, M. Nagano-Fujii, N. Sasase, S. Imoto, S.R. Kim, and H. Hotta Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy Hepatology 48 2008 38 47 (Pubitemid 351975529)
35. A. El-Shamy, S.R. Kim, Y.H. Ide, N. Sasase, S. Imoto, L. Deng, I. Shoji, and H. Hotta Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy Intervirology 55 2012 1 11
36. Y. Yano, Y. Seo, A. Miki, M. Saito, H. Kato, K. Hamano, M. Oya, S. Ouchi, T. Fujisawa, and H. Yamada Mutations in non-structural 5A and rapid viral response to pegylated interferon-alpha-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C Int J Mol Med 30 2012 1048 1052
37. M.J. Gale Jr., M.J. Korth, N.M. Tang, S.L. Tan, D.A. Hopkins, T.E. Dever, S.J. Polyak, D.R. Gretch, and M.G. Katze Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein Virology 230 1997 217 227 (Pubitemid 27211852)
38. K. Kumthip, P. Chusri, N. Jilg, L. Zhao, D.N. Fusco, H. Zhao, K. Goto, D. Cheng, E.A. Schaefer, and L. Zhang Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling J Virol 86 2012 8581 8591
39. G.Z. Gong, J. Cao, Y.F. Jiang, Y. Zhou, and Liu B Hepatitis C virus non-structural 5A abrogates signal transducer and activator of transcription-1 nuclear translocation induced by IFN-alpha through dephosphorylation World J Gastroenterol: WJG 13 2007 4080 4084 (Pubitemid 47323160)
40. K.H. Lan, K.L. Lan, W.P. Lee, M.L. Sheu, M.Y. Chen, Y.L. Lee, S.H. Yen, F.Y. Chang, and S.D. Lee HCV NS5A inhibits interferon-alpha signaling through suppression of STAT1 phosphorylation in hepatocyte-derived cell lines J Hepatol 46 2007 759 767
41. M. Aus dem Siepen, V. Lohmann, M. Wiese, S. Ross, M. Roggendorf, and S. Viazov Nonstructural protein 5A does not contribute to the resistance of hepatitis C virus replication to interferon alpha in cell culture Virology 336 2005 131 136 (Pubitemid 40693947)
42. C.M. Lange, and S. Zeuzem IL28B single nucleotide polymorphisms in the treatment of hepatitis C J Hepatol 55 2011 692 701
43. M. Naito, A. Matsui, M. Inao, S. Nagoshi, M. Nagano, N. Ito, T. Egashira, M. Hashimoto, S. Mishiro, and S. Mochida SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C J Gastroenterol 40 2005 381 388 (Pubitemid 40723929)
44. H. Tsukada, H. Ochi, T. Maekawa, H. Abe, Y. Fujimoto, M. Tsuge, H. Takahashi, H. Kumada, N. Kamatani, and Y. Nakamura A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C Gastroenterology 136 2009 1796 1805 e1796
45. N. Matsuyama, S. Mishiro, M. Sugimoto, Y. Furuichi, M. Hashimoto, M. Hijikata, and Y. Ohta The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon Hepatol Res: Off J Jpn Soc Hepatol 25 2003 221 225 (Pubitemid 36546347)
46. S. Knapp, L.J. Yee, A.J. Frodsham, B.J. Hennig, S. Hellier, L. Zhang, M. Wright, M. Chiaramonte, M. Graves, and H.C. Thomas Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR Genes Immun 4 2003 411 419 (Pubitemid 38967606)
47. Y. Huang, H. Yang, B.B. Borg, X. Su, S.L. Rhodes, K. Yang, X. Tong, G. Tang, C.D. Howell, and H.R. Rosen A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection Proc Natl Acad Sci U S A 104 2007 985 990 (Pubitemid 46154723)
48. S.L. Rhodes, H. Erlich, K.A. Im, J. Wang, J. Li, T. Bugawan, L. Jeffers, X. Tong, X. Su, and H.R. Rosen Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection Genes Immun 9 2008 328 333 (Pubitemid 351791488)
49. L.J. Yee, K. Im, B. Borg, H. Yang, and T.J. Liang Interleukin-6 haplotypes and the response to therapy of chronic hepatitis C virus infection Genes Immun 10 2009 365 372
50. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, T.J. Urban, E.L. Heinzen, P. Qiu, A.H. Bertelsen, and A.J. Muir Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
51. V. Suppiah, M. Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, M.L. Abate, M. Bassendine, U. Spengler, G.J. Dore, and E. Powell IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 2009 1100 1104
52. Y. Tanaka, N. Nishida, M. Sugiyama, M. Kurosaki, K. Matsuura, N. Sakamoto, M. Nakagawa, M. Korenaga, K. Hino, and S. Hige Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 2009 1105 1109
53. A. Rauch, Z. Kutalik, P. Descombes, T. Cai, J. Di Iulio, T. Mueller, M. Bochud, M. Battegay, E. Bernasconi, and J. Borovicka Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study Gastroenterology 138 2010 1338 1345 1345. e1331-1337
54. R.P. Donnelly, and S.V. Kotenko Interferon-lambda: a new addition to an old family J Interferon Cytokine Res: Off J Int Soc Interferon Cytokine Res 30 2010 555 564
55. F. Bellanti, G. Vendemiale, E. Altomare, and G. Serviddio The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C Clin Dev Immunol 2012 2012 849373
56. J.J. McCarthy, J.H. Li, A. Thompson, S. Suchindran, X.Q. Lao, K. Patel, H.L. Tillmann, A.J. Muir, and J.G. McHutchison Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin Gastroenterology 138 2010 2307 2314
57. D.L. Thomas, C.L. Thio, M.P. Martin, Y. Qi, D. Ge, C. O'Huigin, J. Kidd, K. Kidd, S.I. Khakoo, and G. Alexander Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 2009 798 801
58. H.L. Tillmann, A.J. Thompson, K. Patel, M. Wiese, H. Tenckhoff, H.D. Nischalke, Y. Lokhnygina, U. Kullig, U. Gobel, and E. Capka A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice Gastroenterology 139 2010 1586 1592 1592 e1581
59. A. Ruiz-Extremera, J.A. Munoz-Gamez, M.A. Salmeron-Ruiz, P.M. de Rueda, R. Quiles-Perez, A. Gila-Medina, J. Casado, A. Belen Martin, L. Sanjuan-Nunez, and A. Carazo Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children Hepatology 53 2011 1830 1838
60. S. Knapp, U. Warshow, K.M. Ho, D. Hegazy, A.M. Little, A. Fowell, G. Alexander, M. Thursz, M. Cramp, and S.I. Khakoo A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection Gastroenterology 141 2011 320 325 325.e321-e322
61. M. Sarasin-Filipowicz, E.J. Oakeley, F.H. Duong, V. Christen, L. Terracciano, W. Filipowicz, and M.H. Heim Interferon signaling and treatment outcome in chronic hepatitis C Proc Natl Acad Sci U S A 105 2008 7034 7039 (Pubitemid 351754525)
62. L. Chen, I. Borozan, J. Feld, J. Sun, L.L. Tannis, C. Coltescu, J. Heathcote, A.M. Edwards, and I.D. McGilvray Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection Gastroenterology 128 2005 1437 1444 (Pubitemid 40712193)
63. J.J. Feld, S. Nanda, Y. Huang, W. Chen, M. Cam, S.N. Pusek, L.M. Schweigler, D. Theodore, S.L. Zacks, and T.J. Liang Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response Hepatology 46 2007 1548 1563 (Pubitemid 350155537)
64. M. Honda, A. Sakai, T. Yamashita, Y. Nakamoto, E. Mizukoshi, Y. Sakai, M. Nakamura, T. Shirasaki, K. Horimoto, and Y. Tanaka Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C Gastroenterology 139 2010 499 509
65. T.J. Urban, A.J. Thompson, S.S. Bradrick, J. Fellay, D. Schuppan, K.D. Cronin, L. Hong, A. McKenzie, K. Patel, and K.V. Shianna IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C Hepatology 52 2010 1888 1896
66. H. Abe, C.N. Hayes, H. Ochi, M. Tsuge, D. Miki, N. Hiraga, M. Imamura, S. Takahashi, M. Kubo, and Y. Nakamura Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state J Med Virol 83 2011 1597 1607
67. H. Abe, C.N. Hayes, H. Ochi, T. Maekawa, M. Tsuge, D. Miki, F. Mitsui, N. Hiraga, M. Imamura, and S. Takahashi IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy J Hepatol 54 2011 1094 1101
68. F.M. Shebl, D. Maeder, Y. Shao, L. Prokunina-Olsson, E.E. Schadt, and T.R. O'Brien In the absence of HCV infection, interferon stimulated gene expression in liver is not associated with IL28B genotype Gastroenterology 139 2010 1422 1424
69. Y. Asahina, K. Tsuchiya, M. Muraoka, K. Tanaka, Y. Suzuki, N. Tamaki, Y. Hoshioka, Y. Yasui, T. Katoh, and T. Hosokawa Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response Hepatology 55 2012 20 29
70. L. Prokunina-Olsson, B. Muchmore, W. Tang, R.M. Pfeiffer, H. Park, H. Dickensheets, D. Hergott, P. Porter-Gill, A. Mumy, and I. Kohaar A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus Nat Genet 2013
71. W.P. Hofmann, and S. Zeuzem Hepatitis C in 2011: a new standard of care and the race towards IFN-free therapy Nat Rev Gastroenterol Hepatol 9 2012 67 68
72. F. Poordad, J.P. Bronowicki, S.C. Gordon, S. Zeuzem, I.M. Jacobson, M.S. Sulkowski, T. Poynard, T.R. Morgan, C. Molony, and L.D. Pedicone Factors that predict response of patients with hepatitis C virus infection to boceprevir Gastroenterology 143 2012 608 618 e601-e605.
73. A.J. Muir IL28B in the era of direct-acting antivirals for hepatitis C J Clin Gastroenterol 47 2013 222 227
74. N. Akuta, F. Suzuki, M. Hirakawa, Y. Kawamura, H. Sezaki, Y. Suzuki, T. Hosaka, M. Kobayashi, S. Saitoh, and Y. Arase Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy Intervirology 55 2012 231 241
75. K. Chayama, C.N. Hayes, H. Abe, D. Miki, H. Ochi, Y. Karino, J. Toyota, Y. Nakamura, N. Kamatani, and H. Sezaki IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C J Infect Dis 204 2011 84 93
76. M.G. Ghany, D.R. Nelson, D.B. Strader, D.L. Thomas, and L.B. Seeff An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Hepatology 54 2011 1433 1444